💡 This article is the first in our Hormone Health series. Next up: women’s hormone replacement (perimenopause and menopause), followed by men’s testosterone replacement therapy. Each post will build on this foundation, separating hype from evidence.
Hormone symptoms can overlap with many other health issues — what looks like “low testosterone” or “menopause” may actually be thyroid, sleep, or lifestyle related.
Just because a friend felt better on HRT doesn’t mean your symptoms have the same cause. Testing and a full evaluation are key.
Hormone therapy should never be “one-size-fits-all.” Safe treatment means personalized choices — patches, creams, pills, injections, or sometimes no hormones at all.
Regular follow-up with labs and check-ins is essential. Hormone levels, safety markers, and your symptoms all need ongoing monitoring.
The right treatment depends on your goals, health history, and risks — not a pre-set package someone tries to sell you.
For a woman with an average risk (meaning no personal history of breast cancer and no significant family history), the lifetime risk is about 1 in 8 (or roughly 12%). Hormone therapy adds a small annual risk of 0.08% (8 additional cases per 10,000 women) with combined HRT. This small change must be weighed against a woman's individual symptoms and health goals.
Hormones influence nearly every system in the body — from mood, energy, and sleep to metabolism, bone health, and sexual function.
Yet the history of hormone therapy is filled with controversy and myths, leaving patients to navigate a maze of misinformation and fear.
For women, the Women’s Health Initiative (WHI) created decades of fear around estrogen therapy.
For men, testosterone was linked to bodybuilding, doping scandals, and worries about prostate cancer.
Today, better studies and updated guidelines give a clearer picture: hormone replacement can be safe and effective when prescribed carefully, started at the right time, and monitored closely.
When the WHI results were first published in 2002, headlines claimed that HRT caused breast cancer and heart disease. Many women stopped treatment overnight.
But here’s the nuance:
The absolute increase in breast cancer risk was small: about 8 additional cases per 10,000 women per year among those taking combined estrogen-progestin therapy.
It's important to note that these findings apply to women of average risk (meaning no personal history of breast cancer or a significant family history). The study showed an increase of 8 additional cases per 10,000 women per year, which, when you put it into a lifetime context, adds a small annual risk of 0.08%.
This is a tiny fraction on top of an average woman’s overall lifetime risk of about 12% (1 in 8). This is why the study's findings are best understood through personalized risk assessment, not a universal warning.
Women who used estrogen-only therapy (for those who had a hysterectomy) did not see an increased risk — and in some subgroups, breast cancer risk was actually lower.
Mortality outcomes over 18 years of follow-up showed no significant increase in all-cause mortality among women on HRT compared to placebo.
Cognitive health is less clear: the WHI Memory Study suggested estrogen did not protect older women against dementia when started late.
The WHI was vital, but it was also misinterpreted and oversimplified. Modern consensus — reinforced by the NAMS 2022 Position Statement — stresses timing, dose, and individualized care.
For decades, testosterone replacement therapy (TRT) was clouded by associations with anabolic steroid abuse in sports. Legitimate medical replacement was lumped in with performance enhancement.
Prostate cancer has been the biggest fear — but modern evidence tells a different story:
Large trials, including the TRAVERSE study, show no increase in major cardiovascular events with TRT.
Systematic reviews and meta-analyses find no consistent increase in prostate cancer risk with physiologic testosterone replacement.
Current AUA and Endocrine Society guidelines agree: TRT can be safe and effective for men with documented testosterone deficiency, provided they are carefully evaluated and monitored.
The distinction is crucial: replacing low levels back to normal is different from “juicing” with supraphysiologic doses.
Perimenopause = the transition years before periods stop, when hormone levels fluctuate wildly (hot flashes, mood changes, sleep trouble).
Menopause = when periods have stopped for 12 months, and estrogen remains consistently low.
Symptoms vary, but common ones include night sweats, vaginal dryness, low libido, and fatigue.
The AUA guideline on genitourinary syndrome of menopause confirms local vaginal estrogen therapy is safe and effective for dryness, pain, and urinary symptoms.
Testosterone naturally declines about 1% per year after age 30. Not every man with lower levels needs TRT.
True hypogonadism = when the testes or pituitary gland fail to make adequate testosterone, confirmed by labs and symptoms.
Age-related low T = when levels fall but symptoms may be subtle or caused by other health issues (obesity, sleep apnea, stress). Careful evaluation is key.
Brain health & Alzheimer’s: Some observational studies suggest estrogen may protect brain function when started around menopause, but results are mixed. Large human trials are ongoing; animal studies remain more encouraging than human ones.
Metabolism: Both estrogen and testosterone influence fat distribution, insulin sensitivity, and cholesterol. Small clinical studies suggest HRT may lower A1C or improve lipid profiles, but these effects are not universal.
Takeaway: These are exciting areas of research, but not yet reasons alone to start HRT. Benefits, if any, may depend heavily on timing, dose, and the individual.
Get tested — but interpret results carefully. Hormones don’t exist in isolation; context matters.
Choose safe, evidence-based formulations. Oral, patch, gel, injection, or vaginal options — there’s no universal “best.”
Monitor consistently. Labs, symptom tracking, and follow-up visits make HRT safer.
Think lifestyle first. Exercise, sleep, and nutrition remain critical pillars of hormone health.
Individualize the plan. A concierge model ensures therapy evolves with you, not a one-time prescription.
Hormone replacement therapy is not the villain it was once made out to be, nor is it a cure-all. The evidence shows that, when tailored to the right person at the right time, HRT can be a safe and powerful tool for healthy aging.
At ZinovyMed, we use advanced testing, ongoing monitoring, and a personalized concierge approach to make hormone therapy part of a bigger picture: living longer, healthier, and stronger.
Want to learn more? Dr. Ilya recommends a great conversation on the topic from Dr. Peter Attia’s podcast, The Drive, episode titled “Women’s Hormone Health.”
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. doi:10.1001/jama.288.3.321.
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA. 2017;318(10):927–938. doi:10.1001/jama.2017.11217.
The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028.
Kopecky SL, Nissen SE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;388:1091–1102. doi:10.1056/NEJMoa2215025.
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229.
Corona G, Pizzocaro A, Vena W, et al. Testosterone and prostate cancer: a systematic review and meta-analysis. Eur Urol. 2022;82(5):464–481. doi:10.1016/j.eururo.2022.05.006.
American Urological Association. Testosterone Deficiency Guideline. 2018. Available at: https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
American Urological Association. Guideline on Genitourinary Syndrome of Menopause. 2025. Available at: https://www.auanet.org/about-us/media-center/press-center/american-urological-association-releases-new-guideline-on-genitourinary-syndrome-of-menopause
Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. Neurology. 2004;62(11):1945–1951. doi:10.1212/01.WNL.0000129530.88946.41.
Rubin R. “The Drive Podcast with Peter Attia, MD: Women’s Hormone Health.” Spotify. 2023.
⚠️ Medical Disclaimer: This blog post is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for professional medical care or consultation with a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment before undertaking a new healthcare regimen.
ZinovyMed provides personalized, physician-led care focused on prevention, longevity, and your long-term health.
Schedule a Consultation